The genetic disease treatment developer boosted its overall funding to more than $35m, with LabCorp and corporate venturing unit Spectrum Health Ventures investing.

Orig3n, a US-based developer of treatments for rare, inherited genetic diseases, raised $20m on Tuesday from investors including healthcare diagnostics company LabCorp and home care and nursing organisation Spectrum Health.

Hatteras Venture Partners led the round, which included Syno Capital, VC firm KTB’s KTB-Korus Fund, investment firm Mountain Group Partners’ MGC Venture Partners subsidiary, Defta Partners and 180 Degree Capital. Spectrum invested through its Spectrum Health Ventures subsidiary.

Founded in 2014, Orig3n uses DNA testing and personal contact with patients…